Written Description and Enablement in Antibody Patent Claims: International Perspectives on Establishing the Scope of Antibody Claims and Incorporating the Latest Developments into Your Patent Prosecution Strategy
Assistant General Patent Counsel
Eli Lilly and Company
Foley & Lardner LLP
Dr. Sebastian Höpfner
German and European Patent and Trademark Attorney
Bird & Bird (Munich, Germany)
ABE & Partners
- How has the recent Federal Circuit decision in Amgen v Sanofi (Fed. Cir. 2021) raised the enablement bar for antibody patents and what will the implications be going forward?
- Creative strategies for claiming monoclonal antibodies in order to secure the broadest claim possible from the patent office
- Establishing the scope of claims for obtaining antibody patents at the USPTO, EPO, and JPO: what can be found as valid and enforceable antibody patent in the US vs. EU vs. Japan?